IIM
FDMT icon

INTECH Investment Management’s 4D Molecular Therapeutics FDMT Stock Holding History

INTECH Investment Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,746
Closed -$100K – 2158
2026
Q1 		$100K Sell
10,746
-6,882
-39% -$59.9K ﹤0.01% 1893
2025
Q4 		$132K Sell
17,628
-1,023
-5% -$10.4K ﹤0.01% 2099
2025
Q3 		$162K Sell
18,651
-1,446
-7% -$8.64K ﹤0.01% 2139
2025
Q2 		$74.6K Sell
20,097
-19,178
-49% -$67.4K ﹤0.01% 2358
2025
Q1 		$127K Buy
39,275
+17,441
+80% +$82.2K ﹤0.01% 2249
2024
Q4 		$122K Sell
21,834
-2,927
-12% -$23K ﹤0.01% 2165
2024
Q3 		$268K Buy
+24,761
New +$411K ﹤0.01% 1578

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

INTECH Investment Management's FDMT Position: Q2 2026 in Review

INTECH Investment Management sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 10,746 shares — an estimated $100K sold.

INTECH Investment Management first reported a position in FDMT in Q3 2024 and held it in 7 quarters. The position peaked at $268K in Q3 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • INTECH Investment Management reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • INTECH Investment Management sold 10,746 4D Molecular Therapeutics shares in Q2 2026, an estimated $100K.
  • INTECH Investment Management first reported a position in 4D Molecular Therapeutics in Q3 2024 and held it in 7 quarters.
  • INTECH Investment Management's 4D Molecular Therapeutics position peaked at $268K in Q3 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.